The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis

The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis
复制标题

肿瘤浸润淋巴细胞在肝细胞癌中的预后价值:系统评价和荟萃分析

DOI:
10.1038/s41598-017-08128-1
复制
发表时间:
2017-08-08
期刊:
影响因子:
4.6
通讯作者:
Ji, Lei
Ji, Lei
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Yao, Wei;He, Jun-chuang;Ji, Lei

文献摘要

被引文献

相似文献

既往临床研究发现,肿瘤浸润淋巴细胞(TIL)水平与肝细胞癌(HCC)的预后显著相关。然而,这些结论和数据仍然存在争议。我们进行了一项系统回顾和荟萃分析,以评估TIL在HCC患者中的预后价值和临床应用。共有23项相关研究的3173例患者被纳入我们的荟萃分析。结果表明,高水平的CD 8+和CD 3 + TIL对总生存期(OS)具有更好的预后价值,HR为0.71(P= 0.04)和0.63(P= 0.03),与低水平相比,高水平的CD 8+、CD 3+和CD 4 + TIL对无疾病/无复发生存期(DFS/RFS)的影响也是如此,HR为0.66(P= 0.01)、0.60(P= 0.01)和0.79(P= 0.04)。相反,高水平FoxP 3 + TIL对OS和DFS/RFS的预后价值更差,HR分别为2.06(P< 0.00001)和1.77(P< 0.00001)。FoxP 3 +/CD 4+和FoxP 3 +/CD 8+比值与OS和DFS/RFS呈负相关。这些发现表明,TIL可以作为HCC的预后生物标志物。然而,TILs在HCC中的临床应用价值有待进一步研究。
Previous clinical studies have found that the levels of tumor-infiltrating lymphocytes (TILs) significantly correlated with prognosis in hepatocellular carcinoma (HCC). However, these conclusions and data remain controversial. We performed a systematic review and meta-analysis to assess the prognostic value and clinical utilization of TILs in patients with HCC. A total of 23 relevant studies of 3173 patients were included into our meta-analysis. The results demonstrated that high levels of CD8+and CD3+TILs had a better prognostic value on overall survival (OS), with HRs of 0.71 (P= 0.04) and 0.63 (P= 0.03), respectively, compared to low levels, as did high levels of CD8+, CD3+and CD4+TILs on disease/recurrence-free survival (DFS/RFS), with HRs of 0.66 (P= 0.01), 0.60 (P= 0.01) and 0.79 (P= 0.04), respectively. In contrast, high levels of FoxP3+TILs had a worse prognostic value on OS and DFS/RFS, with HRs of 2.06 (P< 0.00001) and 1.77 (P< 0.00001), respectively. The FoxP3+/CD4+and FoxP3+/CD8+ratios negatively correlated with OS and DFS/RFS. These findings suggest that TILs may serve as a prognostic biomarker in HCC. However, further research should be performed to clarify the clinical value of TILs in HCC.